{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:47:58Z","timestamp":1783784878912,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ando.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T11:58:58Z","timestamp":1531310338000},"page":"569-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"79","author":[{"given":"Delphine","family":"Drui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Illouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2018.07.003_bib0185","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2018.07.003_bib0190","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.003_bib0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ando.2018.07.003_bib0200","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2018.07.003_bib0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0210","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2018.07.003_bib0215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","article-title":"Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib","volume":"23","author":"Ohba","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.07.003_bib0220","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"Daimon","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.07.003_bib0230","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/14737140.2014.929501","article-title":"Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta-analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ando.2018.07.003_bib0235","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.07.003_bib0245","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0250","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejrad.2011.06.035","article-title":"Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function","volume":"81","author":"Kitajima","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ando.2018.07.003_bib0255","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/thy.2009.0414","article-title":"Sunitinib induces hypothyroidism with a markedly reduced vascularity","volume":"20","author":"Makita","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.07.003_bib0260","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ando.2018.07.003_bib0265","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-08-0006","article-title":"Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients","volume":"158","author":"Dora","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.07.003_bib0270","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.003_bib0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2018.07.003_bib0280","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/ERC-15-0252","article-title":"Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer","volume":"22","author":"Worden","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2018.07.003_bib0285","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0290","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0295","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.003_bib0300","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.003_bib0305","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.003_bib0310","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.003_bib0315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-12-0828","article-title":"Sorafenib therapy decreases the clearance of thyrotropin","volume":"168","author":"Verloop H1","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.07.003_bib0320","doi-asserted-by":"crossref","first-page":"e0147048","DOI":"10.1371\/journal.pone.0147048","article-title":"Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses","volume":"11","author":"Shu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ando.2018.07.003_bib0325","first-page":"3177","article-title":"Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy","volume":"34","author":"Kust","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ando.2018.07.003_bib0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.07.003_bib0335","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.07.003_bib0340","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1200\/JCO.2012.46.7142","article-title":"Case of sorafenib-induced thyroid storm","volume":"31","author":"Haraldsdottir","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0345","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2016-4025","article-title":"Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma","volume":"102","author":"Beukhof","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.003_bib0350","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/thy.2017.0587","article-title":"Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.07.003_bib0355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11523-011-0197-2","article-title":"Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management","volume":"6","author":"Brown","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.ando.2018.07.003_bib0360","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1684\/bdc.2011.1441","article-title":"Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein\u00a0: effets secondaires endocriniens et troubles m\u00e9taboliques","volume":"98","author":"Caron Ph","year":"2011","journal-title":"Bull Cancer"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426618311818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426618311818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:51:12Z","timestamp":1757717472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426618311818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0003426618311818"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}